药物性肝损伤发病机制研究进展*

doi:10.3969/j.issn.1672-5069.2014.06.027

Abstract

Abstract: DILI is the most important cause of acute liver failure in the U.S. The emerging concept of drug-specific “upstream” events that cause initial hepatocyte injury and less specific“downstream” events described by Kaplowitz,which provides clear direction for further DILI mechanism research. Currently,it’s well-know that the mechanism of DILI is complex,involving drug metabolism, mitochondrial dysfunction,immune response,signal transduction,genetic and environmental et al. Progression of DILI may be the result of the combined effects of multiple factors.

Key words: Drug-induced liver injury, pathogenesis

Ming Yanan, Liu Xiaolin, MaoYimin. The pathogenesis of drug-induced liver injury（DILI）[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(6): 657-661.

References

[1] Larson AM,Polson J,Fontana RJ,et al. Acetaminophen-induced acute liver failure:results of a United States multicenter,prospective study. Hepatology,2005,42:1364-1372.
[2] Senior JR. Drug hepatotoxicity from a regulatory perspective. Clin Liver Dis,2007,11:507-524.
[3] Kuehn BM. Dietary supplement linked to cases of acute hepatitis. JAMA,2013,310（17）:1784.
[4] Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov,2005,4:489-499.
[5] Russmann S,Jetter A,Kullak-Ublick GA. Pharmacogenetics of drug-induced liver injury. Hepatology,2010,52（2）:748-761.
[6] Lammert C,Bjornsson E,Niklasson A,et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology,2010,51:615-620.
[7] Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis ,2007,11:525-548.
[8] Hsin-Tien Ho,Teng-Hsu Wang,Cheng-Huei Hsiong,et al. The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity. Pharmacogenet Genomics,2013,23（4）:200-7.
[9] Mitchell R. McGill,C. David Williams,Yuchao Xie et al. Acetaminophen-induced Liver Injury in Rats and Mice:Comparison of Protein Adducts,Mitochondrial Dysfunction,and Oxidative Stress in the Mechanism of Toxicity.Toxicol Appl Pharmacol,2012,264（3）:387-394.
[10] Jaeschke H,Cover C,and Bajt ML. Role of caspases in acetaminophen-induced liver injury. Life Sci. 2006 Mar 6;78（15）:1670-6. Epub 2005 Oct 13. Adv Exp Med Biol,2001,500:663-73.
[11] Qiu Y,Benet LZ,and Burlingame AL . Identification of hepatic protein targets of the reactive metabolites of the non-hepatotoxic regioisomer of acetaminophen,3-hydroxyacetanilide,in the mouse in vivo using two-dimensional gel electrophoresis and mass spectrometry. Adv Exp Med Biol,2001,500:663-73.
[12] Kon K,Kim JS,Jaeschke H,et al. Mitochondrial permeability transition in acetaminophen-induced necrotic and apoptotic cell death to cultured mouse hepatocytes. Hepatology,2004,40:1170-1179
[13] Jaeschke H,Lemasters JJ .Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology,2003,125:1246-1257.
[14] Bajt ML,Farhood A,Lemasters JJ,et al. Mitochondrial bax translocation accelerates DNA fragmentation and cell necrosis in amurine model of acetaminophen hepatotoxicity. J Pharmacol Exp Ther,2008,324:8-14.
[15] UziD,BardaL,ScaiewiczV,et al.CHOP is a critical regular of acemitophen-induced hepatoxicity.Journal of Hepatology,2013,59:495-503
[16] Fisher JE,McKenzie TJ,Role of Kupffer cells and toll-like receptor 4 in acetaminophen-induced acute liver failure. J Surg Res,2013,180（1）:147-55.
[17] Liu ZX,Govindarajan S,Okamoto S,et al. NK cells cause liver injury and facilitate the induction of T cell mediated immunity to a viral liver infection. J Immunol,2000,164:6480-6486
[18] Lawson JA,Farhood A,Hopper RD,et al. The hepatic inflammatory response after acetaminophen overdose:role of neutrophils. Toxicol Sci,2000,54:509-516.
[19] Cover C,Liu J,Farhood A,Malle E,et al. Pathophysiological role of the acute inflammatory response during acetaminophen hepatotoxicity. Toxicol Appl Pharmacol,2006,216（1）:98-107.
[20] Liu ZX,Govindarajan S,Okamoto S,et al. NK cells cause liver injury and facilitate the induction of T cell mediated immunity to a viral liver infection. J Immunol,2000,164:6480-6486.
[21] Martin-Murphy BV,Kominsky DJ,Orlicky DJ,et al. Increased susceptibility of natural killer T-cell-deficient mice to acetaminophen-induced liver injury. Hepatology,2013,57（4）:1575-84.
[22] Daly AK,Donaldson PT,Bhatnagar P,et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet,2009,41（7）:816-9.
[23] Monshi MM,Faulkner L,Gibson A,et al. Human leukocyte antigen （HLA）-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology,2013,57（2）:727-39.
[24] Patin E,Harmant C,Kidd K K,et al. Sub-saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Hum Mutat,2006,27:720.
[25] Lin J J,Han C-Y,Link B K,Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians,Blacks,Hispanics,and Whites:application to metabolic epidemiology. Am J Human Genet,1993,52:827-834.
[26] Kim S H,Kim S H,Bahn J W,et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics,2009,10:1767-1779.
[27] Chen M,Borlak J,Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology,2013,58（1）:388-96.
[28] Jane F. Maddox,Chidozie J. Amuzie. et al. Bacterial-and Viral-Induced Inflammation Increases Sensitivity to Acetaminophen Hepatotoxicity. Journal of Toxicology and Environmental Health,2010 ,73:58-73.
[29] M. Isabel Lucena. Raul J. Andrade. Neil Kaplowitz. et al. Phenotypic Characterization of Idiosyncratic DrugInduced Liver Injury:The Influence of Age and Sex. Hepatology,2009,49（6）:2001-9.
[30] Stefan Russmann,Alexander Jetter,Gerd A. Kullak-Ublick Pharmacogenetics of Drug-Induced Liver Injury Hepatology,2010,52（2）:748-61.
[31] Daly AK,Donaldson PT,Bhatnagar P,et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet,2009,41（7）:816-9
[32] Kindmark A,Jawaid A,Harbron CG,et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J,2008,8:186-195.
[33] Tang N,Deng R,Wang Y,et al. GSTM1 and GSTT1 null polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury:a meta-analysis. Int J Tuberc Lung Dis,2013,17（1）:17-25
[34] Dávila-Fajardo CL,Swen JJ,Cabeza Barrera J,et al.Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. Pharmacogenomics,2013,14（1）:63-73.
[35] Pande JN,Singh SP,Khilnani GC,et al. Risk factors for hepatotoxicity from antituberculosis drugs:a case-control study.Thorax,1996,51:132-136.
[36] Garcia-Closas M,Hein DW,Silverman D, et al. A single nucleotide polymorphism tags variation in the arylamineN-acetyltransferase 2 phenotype in populations of European background. Pharmacogenet Genomics,2011,21:231-236.
[37] Ho HT,Wang TH,Hsiong CH,et al. The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity. Pharmacogenetics and Genomics,2013,23:200-207.
[38] Anup Ramachandran,Mitchell R. McGill,Yuchao Xie,et al. Receptor Interacting Protein Kinase 3 Is a Critical Early Mediator of Acetaminophen-induced Hepatocyte Necrosis in MiceHepatology,2013,58（6）:2099-108.
[39] Patel SJ,Milwid JM,King KR,et al. Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure. Nat Biotechnol,2012,30（2）:179-83.

The pathogenesis of drug-induced liver injury（DILI）

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Shuai, Yang Changqing.. Pathogenesis and risk factors of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 761-764.
[2]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[3]	Liu Liwei, Zhao Xinyan. Clinicopathological features of drug-induced liver injury [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 160-163.
[4]	Huang Chunyang, Shan Jing, Liao Huiyu, Huang Yunli, Han Ying, Zhang Xiaodan, Du Xiaofei, Ren Meixin, Bian Xinqu, Liu Yanmin. Clinical and laboratory characteristics of patients with drug-induced liver injury receiving glucocorticoid therapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 208-211.
[5]	Wu Xiuxin, Zhang Huiyong, Zhang Kai. Changes of plasma microRNA-4284 in patients with anti-tuberculosis drug-induced hepatotoxicity [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 212-215.
[6]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[7]	Sun Wenjing, Chen Dongfeng.. Literature analysis about RUCAM scale and Maria scale in diagnosis of Chinese patients with drug-induced liver injury [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 881-884.
[8]	Cui Ruibing, Yan Ming.. Etiology of ascites:what’s going on [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 657-660.
[9]	Li Yue, Ding Huiguo.. Current diagnosis and treatment of chylous ascites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 665-668.
[10]	Tong Xin, Fan Hua. Efficacy of bicyclic alcohol on liver function in gastric cancer patients with chemotherapy-induced liver injury [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 625-626.
[11]	Liu Cong, Wang Tingting, Zuo Lili, et al. Analysis of patients with drug-induced liver injury in recent 3 years [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 639-640.
[12]	Liu Liangyi, Su Dongyuan. Comparison of clinical and liver pathological features of patients with drug-induced liver injury and autoimmune hepatitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 463-464.
[13]	Zeng Minde. Mechanisms of lipotoxicity in pathogenesis of nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 153-156.
[14]	Chi Zhaochun. Pathogenesis of nonalcoholic steatohepatitis and cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 166-169.
[15]	Xin Fengzhi, Cao Haixia, Fan Jiangao. Glucagon-like peptide-1 in melioration of non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 313-316.